601607.SH
Shanghai Pharmaceuticals Holding Co., Ltd.
SSE · Healthcare · Medical - Distribution · CN
CNY 16.43
−0.67%Year over year
Reported trailing growth
- Revenue
- +4.4%
- EBITDA
- —
- EBIT
- +29.7%
- EPS
- +33.6%
- Free cash flow
- -25.9%
- Operating cash flow
- -19.2%
Forward estimates
Based on analyst estimates
- Revenue
- -0.1%
- EBITDA
- -11.7%
- EPS
- -14.6%
Three-year CAGR
- Revenue
- +6.9%
- EBITDA
- +4.5%
- EBIT
- +3.3%
- Net income
- +0.6%
- EPS
- -1.5%
- Free cash flow
- +23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026